everyone. Thanks, Olivia, afternoon, and good
Phase to trial Before I in Carol status the update brief key give enrollment our describe from lower-risk MDS. like the Imerge a I'd the in III event, on outcomes
XXXX, As enrollment May. were to countries XX% of enrollment to in to approximately emerge end majority of July of screening sites COVID-XX wane of effects of originally for of are planned clinical clinical the begun as XX% pandemic the the sites located. in and the we trial momentum has patient the reported begin the improve open compared The for XX
associated be delays assumptions, COVID-XX. available to expanding of the second current our to the end to to the enrollment XX year. of approximately by are XX the goals, interruptions and sites, be results XXXX XXXX. to new sites with we line of trial from these top expect potential Under quarter to enrollment enrollment of by open subject clinical expect the expect reach future end achievements we continue for majority or the in completed of continue half the first we Imerge patient We To the to be of XXX
successful very reprised presentations event we the Next, had the I of in KOL total from will Annual highlight key Congress. X where EHA BCR leaders hosted opinion key takeaways June, X from
Dr. patients of mature the more in presented Valeria from Florence, the lower-risk Imerge professor University Phase First, in at Santini, hematology data MDS. II of XX trial associate
indicates the transfusion longer received the duration more at independence. with Phase of weeks months. patients Imerge TI reported, of in HIE than were XX% and set and about X believe per least year very patients Phase These most dependents which transfusion II our transfusion Furthermore, reported and free a we baseline enthusiasm and Transfusion subscripts. as independence will community, observation high observed previously and of of well The at or or a data Imerge especially favorably XX XX XX given hemalignancy dependence, III and both search As important this the baseline high patient activity similar period by they transfusion, patient median negative for have being of and transfusion enrollment. XX generate withing achieved trial been well including as mature data even patients durability transfusion translated, more rates X positive durability XX% disease-modifying with units ongoing trial more of medical an impact of in had X-week median metastatic. XX X
telomerase dependent reviewed program with patients as activity. at expected, action Our patients John telomerase Mascarenas, length all better second director trial reductions of telomerase hTERT, the Furthermore, was inhibition, telomeres MF to the Dr. lower outcomes and Mascarenas the of adult show and or of which, exposure expression very by the levels, in of imetelstat. from [indiscernible]. Imbark as of Dr. pharmacodynamic that exciting in of of these leukemia amenable and activity a professor such markers telomerase analysis, achieved this patients activity, supported telomerase dose previously new and analysis imetelstat presenter mechanism [indiscernible] are patients, of inhibitor associate indicating medicine to known relapsed/refractory more on-target longer shorter telomerase confirming previously clinical was compared with established, and higher as
by presented notably now correlated reductions in in improvement analysis marrow other reported. X, benefits imetelstat was dose-dependent and after that treatment, most Significant addition, were with In also overall showed burden [indiscernible] survival fibrosis. Cala in improvement JAK clinical bone with bipolar
together, of new [indiscernible] of underlying Taken myofibrosis [indiscernible]. imetelstat improvement fibrosis, that the this activity observed reduction analysis malignant OS improvement and in the highlight disease-modifying the indicate targeting potential median by in
patients population. XX% X, our The associated in key by of third vice with XX% treatment the showed event, triple-negative myelofibrosis non data to Imbark. to outcomes MS JAK and who [indiscernible] CALR for and survival department triple-negative of these [indiscernible] also imetelstat clinical represent an response mutations malignant rates overall type at of to called is the improved patient chair compared patients shorter compared The do myelofibrosis leader in opinion not triple-negative limitations. Moffit the months were XX.X XX.X survival triple-negative patients higher triple-negative in new Dr. triple-negative are myofibrosis symptom the inbound Cancer This Rami for hematology months from to at Dr. the carrying the Komrokji, and the True analysis ones. with of non Center have patients. presented compared patients patients
patient clinical Phase intermediate are and in baseline. refractory by study JAK To planned Center. imetelstat danazol, Verstovsek in hydroxyurea Sinai the options had These patients a from imetelstat myelofibrosis. levels and to treatment enrolled Maskerine III trial compare The Cancer X Phase patients eligible MF, with high be X refractory excluding III or them in our further outcome principal study current analyses which led who enroll for global, inhibitor. with from at trial MD and planned to III in support summarize, poor high-risk Phase onboard these therapy, available Serge in triple-negative telomerase collaborators. represent and JAK our the be trial short will patients MF, such will Anderson honored Finally, length will study investigators. best Dr. randomized, as to to expression approximately inhibitor XXX The planned have population refractory patients Dr. Mount while as to is treatment inhibitors. JAK We're open-label John such suitable
plan such XXX over activities OS enrollment of to enrolled of institutional as the review after Start-up for the board open North of or patients analysis, ethics to America, the participation committee expect conducted clinical prespecified, as expect South occurred. screening the Europe as overall analysis trial sites and have a regulatory America, for died. of death have the of the end from Asia. survival than potential we have obtaining registration arms treatment designed is survival to identifying interim sites protocol We finalizing interim analysis planned well statistically events be the up quarter for final projected An to support across be file. between data at authorities. reach If to and to The is by is clearance significant more are of X a could ongoing, analysis We and overall met first trial number total the the final approximately the for XX% the such planned XX% difference XXXX. in
complete the half the to XXXX, are first interim in for half study second expectations patient analysis of XXXX. current the XXXX, and of half of first to Our the final conduct this enrollment in in analysis
imetelstat Phase in high be patient in a could demonstrate analysis successful, are interim the know, you III driven different drug currently first refractory both than prognosis, this and manis will occur poor trial projected. to population. we the at survival and planned this event MF times benefit as believe However, unmet If final need
Chip. I'd Chip? like hand to Now the to back call
